Today: 9 June 2026
Dow Dips as Fed Fears Slam Tech Stocks – Hot Economic Data Rattles Wall Street (Sept 25, 2025)
7 November 2025
3 mins read

Comcast (CMCSA) Stock Today — Nov. 7, 2025: Sky–ITV Talks and a Potential WBD Bid Put M&A in Focus as Shares Hover Near $27

Published: November 7, 2025

Key takeaways

  • CMCSA trades around $27 this afternoon after a choppy session, as investors weigh fresh deal headlines. As of 19:33 UTC (2:33 p.m. ET), shares changed hands at $27.28, within a $27.02–$27.77 intraday range on ~20.9M shares.
  • Sky, owned by Comcast, entered preliminary talks to buy ITV’s U.K. TV unit (including the ITVX streamer) in a deal valued at about £1.6B (~$2.1B)—a move that could boost Comcast’s U.K. footprint but likely faces regulator scrutiny.
  • Reuters reports Comcast has hired bankers and gained data-room access to explore a bid for Warner Bros. Discovery’s studio and streaming assets, keeping consolidation chatter front and center.
  • Recent context: CMCSA closed $27.31 yesterday (Nov. 6) and has lagged peers this year; Barron’s notes shares are down roughly 27% YTD as cord-cutting pressures persist.

Comcast stock price snapshot (Nov. 7, 2025)

Comcast Corporation (NASDAQ: CMCSA) traded modestly lower today, holding near the $27 handle. As of 19:33 UTC (2:33 p.m. ET), the stock printed $27.28 after opening at $27.56, with volume around 20.9 million shares. Intraday, CMCSA ranged $27.02–$27.77, reflecting an active tape as investors reacted to fresh M&A headlines.

For reference, CMCSA finished Thursday at $27.31, setting the baseline for today’s moves.


What’s moving CMCSA today: two deal headlines

1) Sky–ITV talks in the U.K.

ITV confirmed it is in preliminary discussions to sell its free‑to‑air TV business and ITVX streaming platform to Sky, Comcast’s U.K. pay‑TV arm, for about £1.6 billion (~$2.15 billion). Analysts immediately flagged potential competition and media ownership questions, given the combined weight in U.K. TV advertising and Sky’s existing footprint. Any agreement would exclude ITV Studios, which has been the subject of separate industry interest. The news sent ITV shares sharply higher this morning and put a fresh spotlight on Comcast’s international strategy post‑Sky.

2) Comcast weighs a Warner Bros. Discovery bid

Separately, Reuters reports that Comcast has retained Goldman Sachs and Morgan Stanley and obtained data‑room access to evaluate a possible bid for Warner Bros. Discovery’s studio and streaming businesses—a sign of serious diligence even though no offer is guaranteed. The report also notes other potential suitors circling portions of WBD, underscoring an escalating M&A cycle across media.


Why this matters for the stock

The U.K. deal could deepen Comcast’s linear + streaming reach in Europe through Sky while accelerating ITV’s pivot toward content production. But it also poses regulatory risk and integration questions that investors will price in. Meanwhile, a WBD move would be transformational—and complex—given U.S. antitrust dynamics and the strategic overlap with NBCUniversal/Peacock. Both headlines keep optionalities open but also add execution risk, helping explain CMCSA’s subdued intraday reaction despite elevated news flow.


The broader setup investors are watching

  • Year-to-date performance: CMCSA has underperformed in 2025, with Barron’s citing roughly –27% YTD amid broadband pressure and a tougher linear TV backdrop. Today’s tape reflects that cautious posture even as deal speculation swirls.
  • M&A lens: MarketWatch framed Comcast’s stance as more aggressive in the current wave of media consolidation (ITV talks + WBD exploration), positioning the company to reshape its portfolio as consumer viewing and advertising continue shifting to digital.

Near‑term catalysts

  • Versant spin‑off investor day (Dec. 4, 2025): Comcast’s planned spin‑off of most U.S. cable networks—Versant (planned ticker: VSNT)—will host its inaugural Investor Day on Dec. 4 in New York, outlining strategy and financial priorities. Comcast and Versant expect the spin to complete in early 2026, subject to customary conditions. For CMCSA holders, the event could clarify capital allocation and the post‑spin asset mix.
  • Dividend track: Comcast most recently declared a $0.33 quarterly dividend (Oct. 30) with the next payment slated for Feb. 4, 2026 to holders of record Jan. 14, 2026—useful context for income‑oriented investors eyeing total return while the stock consolidates.

Other headlines touching Comcast today (lower impact)

  • Institutional flows: Achmea Investment Management boosted its CMCSA stake in Q2, according to a fresh 13F‑based summary—incremental, but supportive of steady institutional ownership.
  • Local footprint: Comcast announced the opening of a new Xfinity store in San Bruno, CA—minor to the stock but part of ongoing retail/channel updates.

Bottom line

Today’s CMCSA trade is about optionality vs. execution. Sky’s talks for ITV’s TV unit and a reported look at WBD’s studio/streaming assets underline Comcast’s willingness to lean into scale where it sees strategic fit. Those moves could reshape the portfolio—but they also come with regulatory and integration hurdles. With shares hovering near $27, investors appear to be waiting for more concrete deal terms and clarity from the Versant Investor Day before re‑rating the stock.


Disclosure: This article is for informational purposes only and does not constitute investment advice. Always do your own research.

Stock Market Today

  • Pro Portfolio Adds Broadcom and Netflix Shares, Upgrades Broadcom Rating
    June 9, 2026, 10:19 AM EDT. The Pro Portfolio is buying 80 shares of Broadcom (AVGO) at around $405, increasing its holdings to 512 shares (3.4% of the portfolio). It is also purchasing 372 shares of Netflix (NFLX) near $82.35, increasing its stake to 2,107 shares (2.85%). Broadcom's AI chip forecast for H2 2026 is viewed as conservative following a $35 billion private credit deal involving Apollo and Blackstone. The rating for Broadcom is upgraded to One, with a checkpoint price of $330 maintained. Netflix's shares are seen as undervalued despite recent declines, supported by a $25 billion buyback and rising U.S. viewership. Netflix's ad business shows growth potential, reaching 250 million monthly active viewers, reinforcing optimism amidst concerns over consumer spending.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
Bubble or Boom? Magnificent Seven Stocks Face Critical Earnings Showdown
Previous Story

Alphabet (GOOGL) Stock Today, Nov 7, 2025: Shares Slip ~2.6% as YouTube TV–Disney Blackout Persists; DOJ Clears $32B Wiz Deal

Anduril’s Fury (YFQ‑44A) Completes First Flight in 556 Days, Accelerating the Air Force’s CCA Program — What’s New Today (Nov. 10, 2025)
Next Story

Anduril’s Fury (YFQ‑44A) Completes First Flight in 556 Days, Accelerating the Air Force’s CCA Program — What’s New Today (Nov. 10, 2025)

Go toTop